Retinopathy of prematurity is on the rise and a third epidemic has been identified. In spite of extensive research and progress in the understanding of this disease in recent years, 50 000 children worldwide are blinded by this condition each year. The relation between hyperoxia, low-gestational age, growth retardation, oxygen dependent growth factors, and oxidative stress are now being understood more clearly. We know that in the first phase of retinopathy of prematurity, hyperoxia inhibits vascular endothelial growth factor. In the second phase, vascular endothelial growth factor rises, and when insulin-like growth factor-1 reaches a threshold around 32 to 34 weeks postconceptional age, uncontrolled neovascularization may occur. It is not known whether this new knowledge will have implications for future therapy. However, by strictly avoiding hyperoxia, that is, SaO 2 >92-93% and avoiding fluctuations in SaO 2 , it is possible to control and prevent severe retinopathy of prematurity in most cases.
Introduction
Oxygen inhalation in the treatment of premature infants was already suggested by Tarnier in 1899 and the first clinical report was published by Bonnaire in 1891 and reviewed by Engstrom. 1 In the 1930s, continuous oxygen therapy 80% O 2 lasting for several weeks was introduced in Boston in the routine treatment of premature infants. Still, the first case of retrolental fibroplasia (RLF) was not discovered until 1942. The reason was not due to a more aggressive oxygen therapy, but perhaps due to the introduction of a new and tighter incubator that allowed the oxygen concentration in the incubator to be maintained at a higher level. This was an example of how new technology, which seemingly should have led to progress, ended up in a disaster because it was not tested out.
The discovery of the relation between hyperoxia and the development of RLF represented a breaking point in modern neonatology. [2] [3] [4] Not only was the cause of a mysterious and scary disease seemingly understood, it also taught us how important it was to test out every new therapeutic approach in randomized, controlled trials, however, small or evident it appeared. 5 In spite of this understanding, new therapies have repeatedly been introduced without this proper testing and the results have some times been disastrous. It is important to emphasize the clearly logical step to nurse newborn and infants in the prone position.
In spite of the fact that oxygen was discovered as a risk factor of RLF or retinopathy of prematurity (ROP), we are still not able to control this disease. One reason for this may be because we believed we understood the disease. 6 However, recent research has clearly shown the complexity of this condition. We are perhaps now or in the near future reaching the step where we have a satisfactory and profound knowledge of this disease, and this knowledge may represent the first steps to prevent it. This may be particularly important these days because there seems to be a new ROP epidemic, which is on the rise. An explosive increase in severe ROP is seen in low-income countries and 50 000 newborn babies are blinded each year due to ROP. One reason for this is that many countries, especially in Latin America, are now able to get more and more immature babies to survive. However, the means to control oxygen, as well as screening programs and therapy, are often lacking due to financial and personal constraints. 7 Risk factors of retinopathy of prematurity In the first epidemic of ROP in the 1940s and 1950s, hyperoxia and prematurity were the main risk factors identified. During the 1970s and 1980s when the second epidemic of ROP was seen, immaturity per se was the most important risk factor, in spite of a much tighter control of oxygen levels. Also, the infants were smaller and more immature than previous. The third epidemic which now is taking place in low-income countries has several similarities with the first epidemic, since relatively large babies develop ROP. In high-income countries, the median gestational age of babies developing ROP is around 25 weeks, however, in some low-income countries it is more than 30 weeks. 7, 8 In a recent study from New Zealand and Australia, 9 which included newborns with gestational age<32 weeks or 1500 g admitted to level 3 units, a subset of newborns with gestational age<29 weeks who survived to 36 weeks postconceptional age were studied. Of these, approximately 1/10 developed ROP stage 3 or 4.
Gestational age<25 weeks represented the most important risk factor with an odds ratio (OR) of 18.6 (95% CI 10.7 to 32.4) compared with 28 week gestational age infants. Growth retardation classified as birth weight <10th percentile also gave significantly raised OR's, for instance being born in <3rd percentile compared with the 25 to 75th percentile gave an OR of 3.0 (95% CI 1.7 to 5.3). Male gender compared with female had an OR of 1.7 (95% CI 1.2 to 2.3).
Among all the risk factors mentioned in the literature, lowgestational age and birth weight, growth retardation, male gender, hyperoxia, days on oxygen, and septicemia seemed to be the most consistent. [8] [9] [10] Role of oxygen In 1954, Ashton and Cook 4 were the first to establish that oxygen is important in disrupting retinal blood vessel development. Several recent studies have shown a relationship between a high-oxygen saturation and ROP. [11] [12] [13] [14] It seems that a SaO 2 >93% increases the risk for severe ROP and need for therapy. Furthermore, these studies also demonstrated more lung problems, including chronic lung disease, in infants nursed in a high-oxygen saturation. No difference in death or neuro-psychomotor development was found. These studies were recently reviewed. 15 The STOP-ROP study was launched to see if development from prethreshold to threshold ROP can be reduced by hyperoxia. 16 From a theoretical point of view, this makes sense since this may suppress vascular endothelial growth factor (VEGF) and hence, vaso-proliferation. Two groups were studied among babies with SaO 2 <94% in room air: (i) the standard group with SaO 2 between 89 and 95% and (ii) the high-saturation group with SaO 2 between 96 and 99%. Although a tendency for a better outcome regarding the eye was found in the high-saturation group, this group of babies had significantly more lung problems and also needed longer time on oxygen and more days in the hospital. Interestingly, those infants with a SaO 2 >94% in room air who were not included in the STOP-ROP trial had a strong tendency to better outcomes than the high-saturation group in the STOP-ROP trial. 17 This observation indicates that the babies with a spontaneous high saturation were protected from the toxic effect of high saturations in some way or other. It may also reflect that high SaO 2 's do not measure the oxygen tension, which may still vary substantially between the high-saturation room air group and the highsaturation group supplemented with oxygen.
Several studies have shown that fluctuations in SaO 2 may be unfortunate, especially when hyperoxia is followed by hypoxia. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat, 18 and also when fluctuations occur at a relatively high level. 19 In animal models, both extreme fluctuations on an hourly basis and smaller but frequent swings as observed in the nursery, produced retinopathy. 20 One study measuring transcutaneous pO 2 showed that severe ROP was associated with greater oxygen tension variability in the first 2 weeks of life. 21 Retinopathy of prematurity as a free radical disease As ROP has been related to hyperoxia, reactive oxygen species may be involved in this disease. And perhaps ROP is not a single disease, but part of the so-called oxygen radical disease of the newborn. 22, 23 However, surprisingly little information is available to prove or disprove a role of oxidative stress in ROP. Very high concentrations of the free oxygen radical generator, hypoxanthine, have been found in the eyes of babies at risk of developing ROP. 24 Furthermore, it has been shown that the retina is low in several important antioxidants and antioxyenzymes. 25 An indication of free radial involvement is also that some protective effects have been shown by giving the potent antioxidant D-Penicillamine. 26 A metaanalysis has also shown some preventive effects of Vitamin E. 27 Retinopathy of prematurity and angiogenic factors Retinal vessel growth begins during 14 to 15 weeks of gestation starting from the optic nerve and progresses peripherally and anteriorly. The first weeks up to week 21, spindle-shaped mesenchymal precursor cells form capillaries. From then on, vascularization occurs by angiogenesis, during which the vessels grow by budding or sprouting from existing vessels. The progressing vasculature is accompanied by astrocytes, which sense the oxygen level and secrete VEGF as a response to hypoxia, and the capillaries grow toward the VEGF stimulus. [28] [29] [30] [31] Vascular endothelial growth factor is a hypoxia-inducible cytokine that is important in retinal neo-vascularization. Hyperoxia suppresses VEGF mRNA, leading to obliteration caused by apoptosis. This can be partially prevented by exogenous VEGF, or particularly by placental growth factor-1 (PIGF-1), a ligand specific for VEGF receptor-1.
32,33
Retinopathy of prematurity phase 1 With premature birth, normal vascular development that would occur in utero ceases and there is loss of some developing vessels. In 1948, Michaelson 34 hypothesized that an increasing oxygen deficit of the oxygen-consuming retina induces release of angiogenic growth factor. In 1992, this theory was demonstrated by Shweiki et al. 35 and Ferrara et al. 28 that hypoxia induces VEGF. Today, we know that hypoxia stimulates VEGF production, which induces neo-vascularization at the junction between vascularized and nonvascularized retina, with associated complications and in the worse case ending in retinal detachment. [28] [29] [30] [31] [32] [33] In the third trimester of pregnancy, fetal insulin like growth factor-1 (IGF-1) levels rise rapidly in utero 36 and then fall precipitously from in utero levels after premature birth. 37 Insulin like growth factor-1 is consequently low after preterm birth and is in fact initially lowest in those who later develop ROP. 38 , 39 The action of VEGF is dependent on IGF-1, which is transported across the placenta. Insulin like growth factor-1 receptor antagonist supresses retinal neovascularization. Insulin like growth factor-1 is therefore a nonhypoxic regulating factor critical to the development of ROP. 40 In utero VEGF is growing at the front of vessels. In phase 1, triggered by premature birth, IGF-1 is not maintained at in utero levels and IGF-1 drops dramatically. Hyperoxia of the immature retina suppresses VEGF. Therefore, because both VEGF and IGF-1 are low in this phase, vascular growth ceases.
Phase 2
As the retina develops anterior to the nondeveloping vasculature, there is increased oxygen demand, which creates localized physiological hypoxia. This precedes vessel growth and VEGF is expressed in response to hypoxia. With maturation, the nonvascularized retina becomes increasingly metabolically active and consequently hypoxic. Hypoxia leads to high VEGF, which induces neo-vascularization. This pathogen is similar to other proliferative retinopathies and leads to ROP phase 2, which occurs around 32 to 34 weeks postconception. 10, 39 Simultaneously as the infant matures, IGF-1 rises slowly, however, levels are much lower than in term infants. Insulin like growth factor-1 acts partly through control of VEGF activation and is needed to allow maximum VEGF stimulation of new vessel growth. When IGF-1 reaches the threshold needed for VEGF to trigger neo-vascularization, ROP phase 2 is initiated. Insulin like growth factor-1 levels reach this threshold at around 34 weeks gestational age and if VEGF is high, neo-vascularization proliferation proceeds. 32, 39 Growth hormone (GH) seems to be a factor nonrelated to oxygen that plays a role in the regulation of neo-vascularization. Proliferative retinopathy is reduced in transgenic mice expressing a GH receptor antagonist, and GH suppressed neo-vascularization is mediated through inhibition of IGF-1. 32, 33 Transforming growth factor b (TGF-b) is also of importance since it induces VEGF receptor (VEGFR) expression in retinal vascular endothelial cells. TGF-b1 inhibits hyperoxia-induced VEGFR reduction. Retinal pericytes expressing TGF-b1 have increased oxygen resistance. TGF-b1 protects retinal capillaries from hyperoxia-induced loss. TGF-b1 and the VEGFR ligand PIGF-1 further increase protection from hyperoxia-induced degeneration. 41 Consequences for treatment Present therapy for severe ROP is mainly based on cryotherapy or more recently, laser retinal ablation of the avascular retina. These treatments reduces the incidence of blindness by 25%. However, treatment does not improve the chance of good visual acuity (>20/40). Unfavorable structural outcome increased 0.35% per year in treated and 0.51% in controls during 15 years follow-up of the cryotherapy study. 42 As a result, such therapy, therefore, is still insufficient.
A number of antioxidants and nutrients have been or may be tested out. Vitamins A and C supplementation do not seem to reduce the rate of severe ROP. 43, 44 In fact, a high ascorbic acid level at the end of the first week of life indicates worse outcome. A meta-analysis including a limited number of studies and patients found a significant reduction in stage 3 þ (5.3-2.4%) with vitamin E (15-100 mg/kg/day). 27 D-penicillamine is a powerful antioxidant and vasomodulator. 45 Some promising data strongly indicate that this drug may reduce severe ROP. 26, 46 An attractive substance, inositol, 47 will be tested out in a supplementation study organized by the National Institute of Child Health & Human Development (NICHD).
In the future, a control of vasoactive substances may be of interest. In ROP phase 1, it may be important to elevate VEGF and IGF-1, and in phase 2, VEGF should be lowered. Figure 1 indicates some of the future target points to achieve this impact upon neurovascularization. Another target could be to enhance VEGFR-1 by PIGF-1 or TGF-b1. GH inhibits IGF-1 and consequently VEGF. In phase 2, GH could reduce IGF-1, and direct blockers of VEGFR-1 could also be of interest in this phase. However, in order to be successful with such an approach, it is of utmost importance to know exactly which phase of ROP each baby is in. For instance, it is disastrous to induce VEGF if the baby is in phase 2. Another Figure 1 Factors contributing to neovascularization and possible therapeutic interventions: In phase 1 of ROP, both vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) are low. An elevation of IGF-1 and avoidance of hyperoxia may contribute to a higher VEGF. Placental growth factor-1 (PIGF-1) as well as transforming growth factor b (TGF-b1) act directly on VEGF receptor-1 (VEGFR-1), which also may promote neovascularization in phase 1. In phase 2, when neovascularization should be controlled, growth hormone (GH) could be used to inhibit IGF-1, which seems to be too high in this phase. A key to reducing severe ROP is by strict control of the oxygen level in order to avoid both hyperoxia and hypoxia. problem is that these growth factors also play a role in other tissues and organs as well, and the global consequences of adding for instance growth factors or GH is as yet not overseen. This therapeutic approach therefore belongs to the future if it can ever be realized. 30, 32 The most important tool at hand today is therefore a strict control of oxygen saturation. Chow et al. 12 showed it is possible to dramatically reduce ROP by strictly controlling SaO 2 to be <93% in the nursery. This control requires an intense daily effort to teach the entire staff how important it may be to keep the SaO 2 between 85 and 92%. It is also important to avoid fluctuations in SaO 2 , especially at high levels. Bagging of the infants following apnea or suctioning often leads to high SaO 2 peaks. This should be avoided and the staff should be taught to perform bagging without 100% O 2 if not absolutely needed. Therefore, blended oxygen using the appropriate FiO 2 is of importance.
Whether oxygen saturations should differ according to gestational age or advancing postnatal age is not known. However, both the BOOST trial 13 and the STOP-ROP trial 16 showed detrimental effects in children randomized to high-vs. low-saturation regimes around gestational age 30 to 32 weeks and until close to term.
Conclusion
Oxygen has been used as a therapy for premature infants for more than 200 years. Still, 55 years after the relationship between oxygen and ROP was described, this condition is still on the rise, especially in low-income countries. However, it is possible to drastically reduce severe cases by careful control of SaO 2 . The relation between oxygen associated vascular growth factors and oxidative stress seems to be poorly explored and understanding this may give us new insight into the pathogenesis of ROP. Whether antioxidants, such as D-penicillamine, vitamin E, or nutritional factors such as inositol will become part of future therapy is not known. If one is able to control vascular growth factors at the right time, a possible new and powerful tool to eradicate this feared condition would be at hand. There apparently is, however, a long way to go before such therapy can be implemented. The best, simplest, and safest method is to strictly control SaO 2 , which should not exceed 92 to 93% in extremely low birth weight infants. The lower limit is not known and not defined, but many neonatal units have good experience with a lower limit of 85%. In spite of a tremendous progress in this field over the last decade, there are still several unanswered questions, which we will hopefully penetrate in the near future.
